CAS: 2609-49-6; Diethyl 4-Nitrobenzylphosphonate

上下游产品

O,O-diethyl benzylphosphonate sodium diethyl phosphite 4-nitrobenzyl chloride diethyl phosphite potassium saltdiethyl (4-aminobenzyl)phosphonate 5-(4-Nitro-benzylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene 9-(4-nitrobenzylidene)-9H-fluorene 1-(4-Nitrobenzyliden)-2,3-diphenylinden

苯基膦酸二乙酯 以88%的收率获得二乙基(4-硝基苯甲基)磷酸盐
参考文献:Catalytic Antibody Regulated Prodrug Therapy
标题:Catalytic Antibody Regulated Prodrug Therapy
摘要:具有催化活性的抗体,能够催化激活含有羰酸酯(-O-Co-Nh-)的前药,适用于抗体导向的酶抗体前药疗法(adapt),通过催化在羰酸酯位置降解前药的非自发反应机制.非自发反应最好具有bac2机制,前药最好是一种氮芥基芳基羰酸酯.该发明还包括相关的免疫原,使用短过渡态类似物和adapt系统筛选催化活性.

专利信息

专利号:US-9096624-B2
优先权日:2009-06-01
标 题:Amino pyrimidine anticancer compounds
发明人：CREW ANDREW P; SHERMAN DAN; APPARI RAMA DEVI; CHEN XIN; CHILUKURI RAMESH; DONG HANQING; FERRARO CATERINA; FOREMAN KENNETH; GUPTA RAMESH C; LI AN-HU; STOLZ KATHRYN M; VOLK BRIAN; ZAHLER ROBERT
权利人:OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula 1, as shown below and defined herein: n n n n n n n n n n n n and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

专利号:US-9133224-B2
优先权日:2010-11-29
标 题:Macrocyclic kinase inhibitors
发明人：CREW ANDREW P; DONG HANQING; FERRARO CATERINA; SHERMAN DAN; SIU KAM W
权利人:CREW ANDREW P; DONG HANQING; FERRARO CATERINA; SHERMAN DAN; SIU KAM W; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.